Bayer HealthCare is investing more than €500 million to establish manufacturing capacity for recombinant factor VIII (rFVIII) hemophilia products that are currently in development at its sites in Wuppertal and Leverkusen, Germany. The company’s two investigational therapies for hemophilia A are currently in Phase III development. Bayer’s approved hemophilia A product is manufactured exclusively in Berkeley, CA. The additional supply source in Germany will help prepare for production of the new therapies upon approval.  

“This investment will be one of the largest in the history of Bayer HealthCare and reflects our strong commitment in the hemophilia field,” said Dr. Olivier Brandicourt, chief executive officer of Bayer HealthCare.